Adenosquamous cell lung cancer successfully treated with gefitinib: A case report

Kurishima,Koichi; Ohara,Gen; Kagohashi,Katsunori; Watanabe,Hiroko; Takayashiki,Norio; Ishibashi,Atsushi; Satoh,Hiroaki

doi:10.3892/mco.2013.221

Adenosquamous cell lung cancer successfully treated with gefitinib: A case report

Authors:
- Koichi Kurishima
- Gen Ohara
- Katsunori Kagohashi
- Hiroko Watanabe
- Norio Takayashiki
- Atsushi Ishibashi
- Hiroaki Satoh
View Affiliations

Affiliations: Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310‑0015, Japan, Division of Pathology, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310‑0015, Japan, Division of Surgery, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310‑0015, Japan
Published online on: December 9, 2013 https://doi.org/10.3892/mco.2013.221
Pages: 282-284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although adenosquamous cell lung cancer (ASCLC) is included in the non‑small‑cell lung cancers (NSCLCs), the number of currently available studies on the response of this type of cancer to epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) is limited. This is the case report of a 66‑year‑old female who was referred to the Mito Medical Center (Mito, Japan) with hemoptysis and the chest computed tomography (CT) scan revealed a large cavitary mass in the lower lobe of the left lung. The patient underwent surgical resection of the lesion and the final pathological diagnosis was ASCLC staged as pT2bN2M0. Notably, an EGFR exon 19 deletion was identified in the adenocarcinomatous as well as the squamous cell carcinomatous components of the tumor. Despite adjuvant chemotherapy, the patient developed small cavitary metastases in the lungs bilaterally. Therefore, treatment with gefitinib was initiated. The chest CT scan revealed substantial regression of the metastatic cavitary tumors in both lungs, with thinning of the walls. The patient remains alive and recurrence‑free 19 months following the initiation of gefitinib therapy. This case demonstrated an optimal clinical response to gefitinib treatment for EGFR mutation‑positive ASCLC, suggesting that gefitinib is a therapeutic option for such a subset of patients with ASCLC.

View Figures

View References

1	D’Incecco A and Cappuzzo F: Gefitinib for non-small-cell lung cancer treatment. Expert Opin Drug Saf. 10:987–996. 2011.
2	Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press; Lyon: 2004
3	Qin BM, Chen X, Zhu JD and Pei DQ: Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res. 15:212–217. 2005. View Article : Google Scholar : PubMed/NCBI
4	Ohtsuka K, Ohnishi H, Fujiwara M, et al: Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer. 109:741–750. 2007. View Article : Google Scholar
5	Kang SM, Kang HJ, Shin JH, et al: Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer. 109:581–587. 2007. View Article : Google Scholar : PubMed/NCBI
6	Niho S, Yokose T, Kodama T, Nishiwaki Y and Mukai K: Clonal analysis of adenosquamous carcinoma of the lung. Jpn J Cancer Res. 90:1244–1247. 1999. View Article : Google Scholar : PubMed/NCBI
7	Kanazawa H, Ebina M, Ino-Oka N, et al: Transition from squamous cell carcinoma to adenocarcinoma in adenosquamous carcinoma of the lung. Am J Pathol. 156:1289–1298. 2000. View Article : Google Scholar : PubMed/NCBI
8	Toyooka S, Yatabe Y, Tokumo M, et al: Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. Int J Cancer. 118:1588–1590. 2006. View Article : Google Scholar : PubMed/NCBI
9	Huang SF, Liu HP, Li LH, et al: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 10:8195–8203. 2004. View Article : Google Scholar : PubMed/NCBI
10	Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar
11	Sasaki H, Endo K, Yukiue H, Kobayashi Y, Yano M and Fujii Y: Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. Lung Cancer. 55:129–130. 2007. View Article : Google Scholar : PubMed/NCBI
12	Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 23:2513–2520. 2005. View Article : Google Scholar
13	Shukuya T, Takahashi T, Kaira R, et al: Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci. 102:1032–1037. 2011. View Article : Google Scholar : PubMed/NCBI
14	Alberg AJ, Brock MV and Samet JM: Epidemiology of lung cancer: looking to the future. J Clin Oncol. 23:3175–3185. 2005. View Article : Google Scholar : PubMed/NCBI
15	Ruffini E, Rena O, Oliaro A, et al: Lung tumors with mixed histologic pattern. Clinico-pathologic characteristics and prognostic significance. Eur J Cardiothorac Surg. 22:701–707. 2002. View Article : Google Scholar : PubMed/NCBI
16	de Jong WK, Schaapveld M, Blaauwgeers JL and Groen HJ: Pulmonary tumours in the Netherlands: focus on temporal trends in histology and stage and on rare tumours. Thorax. 63:1096–1102. 2008.PubMed/NCBI
17	Sugimoto Y, Semba H, Fujii S, Furukawa E and Kurano R: Clinical analysis of primary lung cancer with a thin-walled cavity to explain the mechanism of thin-walled cavity formation. Nihon Kokyuki Gakkai Zasshi. 45:460–464. 2007.(In Japanese).
18	Kazerooni EA, Bhalla M, Shepard JA and McLoud TC: Adenosquamous carcinoma of the lung: radiologic appearance. AJR Am J Roentgenol. 163:301–306. 1994. View Article : Google Scholar : PubMed/NCBI
19	Honda O, Tsubamoto M, Inoue A, et al: Pulmonary cavitary nodules on computed tomography: differentiation of malignancy and benignancy. J Comput Assist Tomogr. 31:943–949. 2007. View Article : Google Scholar : PubMed/NCBI